Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
51
OABI Quote, Financials, Valuation and Earnings
Last price:
$1.93
Seasonality move
:
-10.64%
Day range:
$1.85 - $2.00
52-week range:
$1.22 - $4.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
10.02x
P/B ratio:
1.02x
Volume:
420.4K
Avg. volume:
620K
1-year change:
-44.48%
Market cap:
$282.2M
Revenue:
$26.4M
EPS (TTM):
-$0.59
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OABI
OmniAb, Inc.
|
$5.6M | -$0.14 | -16.67% | -29.83% | $7.33 |
|
FHTX
Foghorn Therapeutics, Inc.
|
$6.2M | -$0.30 | 232.63% | -23.03% | $11.67 |
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
KPTI
Karyopharm Therapeutics, Inc.
|
$42.4M | -$3.25 | 17.34% | -47.52% | $14.67 |
|
NKTR
Nektar Therapeutics
|
$10.2M | -$2.79 | -64.24% | -1474.64% | $114.43 |
|
ZVRA
Zevra Therapeutics, Inc.
|
$26.6M | -$0.02 | 132.94% | -99.63% | $22.54 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OABI
OmniAb, Inc.
|
$1.96 | $7.33 | $282.2M | -- | $0.00 | 0% | 10.02x |
|
FHTX
Foghorn Therapeutics, Inc.
|
$5.40 | $11.67 | $305.4M | -- | $0.00 | 0% | 13.46x |
|
GTBP
GT Biopharma, Inc.
|
$0.85 | $8.00 | $9M | -- | $0.00 | 0% | 59.35x |
|
KPTI
Karyopharm Therapeutics, Inc.
|
$7.47 | $14.67 | $127.4M | -- | $0.00 | 0% | 0.45x |
|
NKTR
Nektar Therapeutics
|
$43.94 | $114.43 | $760.2M | -- | $0.00 | 0% | 45.31x |
|
ZVRA
Zevra Therapeutics, Inc.
|
$8.64 | $22.54 | $486.4M | 13.70x | $0.00 | 0% | 5.59x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OABI
OmniAb, Inc.
|
7.06% | 2.112 | 9.15% | 4.71x |
|
FHTX
Foghorn Therapeutics, Inc.
|
-33.56% | 2.098 | 8.15% | 2.13x |
|
GTBP
GT Biopharma, Inc.
|
-- | -0.510 | 4.06% | 1.98x |
|
KPTI
Karyopharm Therapeutics, Inc.
|
-269.68% | 1.256 | 345.14% | 0.89x |
|
NKTR
Nektar Therapeutics
|
66.26% | 7.157 | 16.97% | 4.07x |
|
ZVRA
Zevra Therapeutics, Inc.
|
32.02% | 1.762 | 11.73% | 8.25x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OABI
OmniAb, Inc.
|
-$2.4M | -$18.2M | -21.16% | -22.86% | -811.26% | -$9.9M |
|
FHTX
Foghorn Therapeutics, Inc.
|
$7.3M | -$18.5M | -- | -- | -226.92% | -$18.9M |
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
KPTI
Karyopharm Therapeutics, Inc.
|
$41.8M | -$15.2M | -1579.24% | -- | -34.56% | -$5.9M |
|
NKTR
Nektar Therapeutics
|
$11.6M | -$31.5M | -54.14% | -327.67% | -267.45% | -$48.9M |
|
ZVRA
Zevra Therapeutics, Inc.
|
$24.5M | $4.1M | 24.95% | 44.06% | 15.9% | $4.2M |
OmniAb, Inc. vs. Competitors
-
Which has Higher Returns OABI or FHTX?
Foghorn Therapeutics, Inc. has a net margin of -738.05% compared to OmniAb, Inc.'s net margin of -194.4%. OmniAb, Inc.'s return on equity of -22.86% beat Foghorn Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OABIOmniAb, Inc.-109.2% -$0.14 $298.5M FHTXFoghorn Therapeutics, Inc.88.96% -$0.25 -$67.1M -
What do Analysts Say About OABI or FHTX?
OmniAb, Inc. has a consensus price target of $7.33, signalling upside risk potential of 274.15%. On the other hand Foghorn Therapeutics, Inc. has an analysts' consensus of $11.67 which suggests that it could grow by 116.05%. Given that OmniAb, Inc. has higher upside potential than Foghorn Therapeutics, Inc., analysts believe OmniAb, Inc. is more attractive than Foghorn Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OABIOmniAb, Inc.7 0 0 FHTXFoghorn Therapeutics, Inc.9 0 0 -
Is OABI or FHTX More Risky?
OmniAb, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Foghorn Therapeutics, Inc. has a beta of 3.043, suggesting its more volatile than the S&P 500 by 204.304%.
-
Which is a Better Dividend Stock OABI or FHTX?
OmniAb, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Foghorn Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OmniAb, Inc. pays -- of its earnings as a dividend. Foghorn Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OABI or FHTX?
OmniAb, Inc. quarterly revenues are $2.2M, which are smaller than Foghorn Therapeutics, Inc. quarterly revenues of $8.2M. OmniAb, Inc.'s net income of -$16.5M is lower than Foghorn Therapeutics, Inc.'s net income of -$15.8M. Notably, OmniAb, Inc.'s price-to-earnings ratio is -- while Foghorn Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OmniAb, Inc. is 10.02x versus 13.46x for Foghorn Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OABIOmniAb, Inc.10.02x -- $2.2M -$16.5M FHTXFoghorn Therapeutics, Inc.13.46x -- $8.2M -$15.8M
-
Which has Higher Returns OABI or GTBP?
GT Biopharma, Inc. has a net margin of -738.05% compared to OmniAb, Inc.'s net margin of --. OmniAb, Inc.'s return on equity of -22.86% beat GT Biopharma, Inc.'s return on equity of -626.24%.
Company Gross Margin Earnings Per Share Invested Capital OABIOmniAb, Inc.-109.2% -$0.14 $298.5M GTBPGT Biopharma, Inc.-- -$0.83 $3M -
What do Analysts Say About OABI or GTBP?
OmniAb, Inc. has a consensus price target of $7.33, signalling upside risk potential of 274.15%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 846.75%. Given that GT Biopharma, Inc. has higher upside potential than OmniAb, Inc., analysts believe GT Biopharma, Inc. is more attractive than OmniAb, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OABIOmniAb, Inc.7 0 0 GTBPGT Biopharma, Inc.1 0 0 -
Is OABI or GTBP More Risky?
OmniAb, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.
-
Which is a Better Dividend Stock OABI or GTBP?
OmniAb, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OmniAb, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OABI or GTBP?
OmniAb, Inc. quarterly revenues are $2.2M, which are larger than GT Biopharma, Inc. quarterly revenues of --. OmniAb, Inc.'s net income of -$16.5M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, OmniAb, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OmniAb, Inc. is 10.02x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OABIOmniAb, Inc.10.02x -- $2.2M -$16.5M GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M
-
Which has Higher Returns OABI or KPTI?
Karyopharm Therapeutics, Inc. has a net margin of -738.05% compared to OmniAb, Inc.'s net margin of -75.21%. OmniAb, Inc.'s return on equity of -22.86% beat Karyopharm Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OABIOmniAb, Inc.-109.2% -$0.14 $298.5M KPTIKaryopharm Therapeutics, Inc.94.93% -$3.82 -$72.8M -
What do Analysts Say About OABI or KPTI?
OmniAb, Inc. has a consensus price target of $7.33, signalling upside risk potential of 274.15%. On the other hand Karyopharm Therapeutics, Inc. has an analysts' consensus of $14.67 which suggests that it could grow by 96.34%. Given that OmniAb, Inc. has higher upside potential than Karyopharm Therapeutics, Inc., analysts believe OmniAb, Inc. is more attractive than Karyopharm Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OABIOmniAb, Inc.7 0 0 KPTIKaryopharm Therapeutics, Inc.3 1 0 -
Is OABI or KPTI More Risky?
OmniAb, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Karyopharm Therapeutics, Inc. has a beta of 0.228, suggesting its less volatile than the S&P 500 by 77.201%.
-
Which is a Better Dividend Stock OABI or KPTI?
OmniAb, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Karyopharm Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OmniAb, Inc. pays -- of its earnings as a dividend. Karyopharm Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OABI or KPTI?
OmniAb, Inc. quarterly revenues are $2.2M, which are smaller than Karyopharm Therapeutics, Inc. quarterly revenues of $44M. OmniAb, Inc.'s net income of -$16.5M is higher than Karyopharm Therapeutics, Inc.'s net income of -$33.1M. Notably, OmniAb, Inc.'s price-to-earnings ratio is -- while Karyopharm Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OmniAb, Inc. is 10.02x versus 0.45x for Karyopharm Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OABIOmniAb, Inc.10.02x -- $2.2M -$16.5M KPTIKaryopharm Therapeutics, Inc.0.45x -- $44M -$33.1M
-
Which has Higher Returns OABI or NKTR?
Nektar Therapeutics has a net margin of -738.05% compared to OmniAb, Inc.'s net margin of -301.29%. OmniAb, Inc.'s return on equity of -22.86% beat Nektar Therapeutics's return on equity of -327.67%.
Company Gross Margin Earnings Per Share Invested Capital OABIOmniAb, Inc.-109.2% -$0.14 $298.5M NKTRNektar Therapeutics98.34% -$1.87 $252.2M -
What do Analysts Say About OABI or NKTR?
OmniAb, Inc. has a consensus price target of $7.33, signalling upside risk potential of 274.15%. On the other hand Nektar Therapeutics has an analysts' consensus of $114.43 which suggests that it could grow by 160.42%. Given that OmniAb, Inc. has higher upside potential than Nektar Therapeutics, analysts believe OmniAb, Inc. is more attractive than Nektar Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings OABIOmniAb, Inc.7 0 0 NKTRNektar Therapeutics6 1 0 -
Is OABI or NKTR More Risky?
OmniAb, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.268, suggesting its more volatile than the S&P 500 by 26.844%.
-
Which is a Better Dividend Stock OABI or NKTR?
OmniAb, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OmniAb, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OABI or NKTR?
OmniAb, Inc. quarterly revenues are $2.2M, which are smaller than Nektar Therapeutics quarterly revenues of $11.8M. OmniAb, Inc.'s net income of -$16.5M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, OmniAb, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OmniAb, Inc. is 10.02x versus 45.31x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OABIOmniAb, Inc.10.02x -- $2.2M -$16.5M NKTRNektar Therapeutics45.31x -- $11.8M -$35.5M
-
Which has Higher Returns OABI or ZVRA?
Zevra Therapeutics, Inc. has a net margin of -738.05% compared to OmniAb, Inc.'s net margin of -2.09%. OmniAb, Inc.'s return on equity of -22.86% beat Zevra Therapeutics, Inc.'s return on equity of 44.06%.
Company Gross Margin Earnings Per Share Invested Capital OABIOmniAb, Inc.-109.2% -$0.14 $298.5M ZVRAZevra Therapeutics, Inc.94.04% -$0.01 $195.9M -
What do Analysts Say About OABI or ZVRA?
OmniAb, Inc. has a consensus price target of $7.33, signalling upside risk potential of 274.15%. On the other hand Zevra Therapeutics, Inc. has an analysts' consensus of $22.54 which suggests that it could grow by 160.92%. Given that OmniAb, Inc. has higher upside potential than Zevra Therapeutics, Inc., analysts believe OmniAb, Inc. is more attractive than Zevra Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OABIOmniAb, Inc.7 0 0 ZVRAZevra Therapeutics, Inc.6 0 0 -
Is OABI or ZVRA More Risky?
OmniAb, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zevra Therapeutics, Inc. has a beta of 1.009, suggesting its more volatile than the S&P 500 by 0.92699999999999%.
-
Which is a Better Dividend Stock OABI or ZVRA?
OmniAb, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OmniAb, Inc. pays -- of its earnings as a dividend. Zevra Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OABI or ZVRA?
OmniAb, Inc. quarterly revenues are $2.2M, which are smaller than Zevra Therapeutics, Inc. quarterly revenues of $26.1M. OmniAb, Inc.'s net income of -$16.5M is lower than Zevra Therapeutics, Inc.'s net income of -$544K. Notably, OmniAb, Inc.'s price-to-earnings ratio is -- while Zevra Therapeutics, Inc.'s PE ratio is 13.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OmniAb, Inc. is 10.02x versus 5.59x for Zevra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OABIOmniAb, Inc.10.02x -- $2.2M -$16.5M ZVRAZevra Therapeutics, Inc.5.59x 13.70x $26.1M -$544K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 0.55% over the past day.
Buy
64
ZCSH alert for Dec 26
Grayscale Zcash Trust (ZEC) [ZCSH] is down 0.71% over the past day.
Buy
66
ASTS alert for Dec 26
AST Spacemobile, Inc. [ASTS] is down 7.66% over the past day.
